Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease

Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease

<h4>Background</h4> <p>The multiple disease domains affected in psoriatic arthritis (PsA) may make composite endpoints appropriate for assessing changes in disease activity over time. Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA. Data from two phase 3 stu...

书目详细资料
Main Authors:	Helliwell, P, Coates, L, Fitzgerald, O, Nash, P, Soriano, E, Husni, M, Hsu, M, Kanik, K, Hendrikx, T, Wu, J, Kudlacz, E
格式:	Journal article
出版:	BioMed Central 2018

相似书籍

Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease
由: Philip Helliwell, et al.
出版: (2018-10-01)

Tofacitinib improves composite endpoint measures of disease in patients with psoriatic arthritis
由: Helliwell, P, et al.
出版: (2018)

Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study
由: Nash, P, et al.
出版: (2018)

Safety and efficacy of Tofacitinib, an oral Janus Kinase inhibitor, up to 36 Months in patients with active Psoriatic Arthritis: data from the third interim analysis of OPAL balance, an Open-Label, long-term extension study
由: Nash, P, et al.
出版: (2018)

Janus kinase inhibitors in the treatment of psoriatic arthritis
由: E. Yu. Loginova, et al.
出版: (2022-02-01)

Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?
由: Coates, L, et al.
出版: (2016)

Assessing disease activity in psoriatic arthritis: a literature review
由: Tucker, L, et al.
出版: (2018)

A novel treatment for psoriatic arthritis: Janus kinase inhibitors
由: Miao Chen, et al.
出版: (2020-04-01)

Sustained very low disease activity and remission in psoriatic arthritis patients
由: Lubrano, E, et al.
出版: (2019)

Current concepts and unmet needs in psoriatic arthritis
由: Mahmood, F, et al.
出版: (2017)

Efficacy of tofacitinib for the treatment of psoriatic arthritis: pooled analysis of two phase 3 studies
由: Nash, P, et al.
出版: (2018)

Remission in psoriatic arthritis—where are we now?
由: Coates, L, et al.
出版: (2017)

THE DIAGNOSIS OF PSORIATIC ARTHRITIS
由: P.S. Helliwell
出版: (2011-09-01)

Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients
由: Ennio Lubrano, et al.
出版: (2019-08-01)

Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
由: Coates, LC, et al.
出版: (2024)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in Phase 3 studies of tofacitinib
由: Coates, L, et al.
出版: (2021)

Ixekizumab makes very low disease activity and remission with psoriatic arthritis disease activity score possible in active psoriatic arthritis patients for up to 1 year: spirit-p1 and spirit-p2 trials
由: Coates, L, et al.
出版: (2018)

Best-practice indicators in Psoriatic disease care
由: Helliwell, P, et al.
出版: (2019)

New GRAPPA recommendations for the management of psoriasis and psoriatic arthritis: process, challenges and implementation
由: Coates, L, et al.
出版: (2016)

What should be the primary target of "treat to target" in psoriatic arthritis?
由: Coates, LC, et al.
出版: (2018)

Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies
由: Peter Nash, et al.
出版: (2018-11-01)

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
由: Mease, P, et al.
出版: (2018)

Psoriatic arthritis
由: FitzGerald, O, et al.
出版: (2021)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib
由: Laura C. Coates, et al.
出版: (2021-03-01)

Efficacy and safety of Janus kinase inhibitors in the treatment of psoriasis and psoriatic arthritis: An analysis of evidence from 2014 to 2022
由: Jiao Wang, et al.
出版: (2025-02-01)

Treat-to-target in psoriatic arthritis—cost-effective in the biosimilar era
由: Coates, L, et al.
出版: (2022)

GRAPPA 2021 treatment recommendations for psoriatic arthritis
由: Soriano, ER, et al.
出版: (2023)

Psoriatic Arthritis: A Review
由: Farrouq Mahmood, et al.
出版: (2016-07-01)

Evaluation and validation of a patient completed psoriatic arthritis flare questionnaire
由: Helliwell, PS, et al.
出版: (2021)

Nail disease in psoriatic arthritis. Data from the Russian Psoriatic Arthritis Registry
由: E. E. Gubar, et al.
出版: (2021-10-01)

Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
由: Laure Gossec, et al.
出版: (2024-02-01)

How should we define disease and outcomes in axial psoriatic arthritis?
由: Coates, LC
出版: (2021)

Hot topice debate: preventing psoriatic arthritis in patients with psoriasis
由: Vivekanantham, A, et al.
出版: (2024)

Measuring outcomes in psoriatic arthritis
由: Ogdie, A, et al.
出版: (2020)

Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis
由: Vishal R. Tandon, et al.
出版: (2022-07-01)

Axial spondyloarthritis and psoriatic arthritis: mostly overlapping or substantially different diseases?
由: Braun, J, et al.
出版: (2023)

Real‐World Evidence Assessing Psoriatic Arthritis by Disease Domain: An Evaluation of the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
由: Philip J. Mease, et al.
出版: (2023-08-01)

Association between patient perception of disease status and different components of the Minimal Disease Activity (MDA) criteria in psoriatic arthritis
由: Yazji, SM, et al.
出版: (2025)

Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study
由: Nash, P, et al.
出版: (2021)

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021
由: Coates, LC, et al.
出版: (2022)